Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Summary
Patients with refractory/relapse hematologic oncology disease may benefit from innovative therapy such as Car-T cells. Factors strongly predictive of outcome and response are unknown. Extracellular vesicles are recognized as a mode of intercellular communication and are reminiscent of the cell of origin. They are currently candidates to be biomarkers for this biomarker of phenomena occurring in tissues. The working hypothesis is that they may be predictive of outcome and toxicity, as some preliminary data have suggested. Therefore, the aim of the study concerns I dentification of potential CAR-EV biomarkers associated with neurological toxicity after infusion of CAR-T cells.
Official title: Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapy
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2024-08-31
Completion Date
2026-08-31
Last Updated
2024-12-27
Healthy Volunteers
No
Conditions
Interventions
Patients who are candidates for CAR-T cell therapy for hematologic malignancy
This study will include patients who undergo CAR-T cell infusion at participating centers during the 18-month duration of the enrollment period. A total of 100 patients are expected to be enrolled, including 80 patients for the prospective part and 20 for the retrospective part.
Locations (1)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy